FDA Inspection 833823 — Hospira, Inc.

Hospira, Inc. — FEI 1021343

The FDA completed an inspection of Hospira, Inc. on March 1, 2013 in Rocky Mount, NC. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 20 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 1, 2013
Fiscal Year
2013
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Rocky Mount, NC (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
111121 CFR 211.25(a)Training , Education , Experience overall
117721 CFR 211.63Equipment Design, Size and Location
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
135821 CFR 211.100(b)SOPs not followed / documented
136121 CFR 211.100(a)Absence of Written Procedures
143121 CFR 211.42(c)(10)(ii)Temperature / Humidity Controls
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
143521 CFR 211.42(c)(10)(v)Cleaning System
145121 CFR 211.113(b)Procedures for sterile drug products
145221 CFR 211.113(b)Validation lacking for sterile drug products
188321 CFR 211.165(a)Testing and release for distribution
202621 CFR 211.192Quality control unit review of records
202721 CFR 211.192Investigations of discrepancies, failures
203121 CFR 211.194(a)Complete test data included in records
354721 CFR 211.46(b)Equipment for Environmental Control
356521 CFR 211.58Buildings not maintained in good state of repair
359421 CFR 211.110(d)Rejected in-process materials not quarantined
360321 CFR 211.160(b)Scientifically sound laboratory controls
434421 CFR 211.160(b)(1)Sampling and testing procedures described